FDA approves Gilead's triple-drug HIV treatment: 4 things to know

The FDA on Wednesday approved Gilead Sciences' HIV drug Biktarvy, reports Reuters.

Here are four things to know.

1. Biktarvy is a once-daily, triple-combination tablet used to treat HIV infections.

2. The drug's wholesale price will be about $36,000 per year, which falls in line with prices of other HIV treatments on the market.

3. Biktarvy contains a boxed warning about exacerbating hepatitis B infections in some patients.

4. ViiV Healthcare filed a lawsuit shortly after Biktarvy's approval, claiming the drug infringed on patents for its own triple-drug HIV treatment.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars